Does the immune system naturally protect against cancer?

Frontiers in Immunology

Volumn 5, Issue MAY, 2014, Pages

  Corthay, Alexandre ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Cancer immunosurveillance; Cancer risk; Checkpoint blockade; HIV; Immunosuppressive drugs; NKG2D; Organ transplantation; Primary immunodeficiency

Indexed keywords

CD28 ANTIGEN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; INTERLEUKIN 10; IPILIMUMAB; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSFORMING GROWTH FACTOR BETA;

CANCER PREVENTION; CANCER RISK; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KAPOSI SARCOMA; LUNG CANCER; NEOPLASM; ORGAN TRANSPLANTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; REVIEW; SOMATIC MUTATION;

EID: 84905500282     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00197     Document Type: Review

References (103)

1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res (1970) 13:1-27.
2. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J (1957) 1:841-7. doi: 10.1136/bmj.1.5023.841
3. Thomas L. Discussion. In: Lawrence HS editor. Cellular and Humoral Aspects of the Hypersensitive States. New York: Hoeber-Harper (1959). p. 529-32.
4. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med (1982) 55:329-33.
5. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 337:1678-84. doi:10.1126/science.1224922
6. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2:293-9. doi:10.1038/86297
7. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol (1996) 8:271-80. doi:10.1006/smim.1996.0035
8. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature (2005) 437:141-6. doi:10.1038/nature03954
9. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (2001) 357:539-45. doi:10.1016/S0140-6736(00)04046-0
10. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature (2008) 454:436-44. doi:10.1038/nature07205
11. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer (1971) 28:89-98. doi:10.1002/1097-0142(197107)28:1<89::AID-CNCR2820280117>3.0.CO;2-Q
12. Kinlen LJ, Webster AD, Bird AG, Haile R, Peto J, Soothill JF, et al. Prospective study of cancer in patients with hypogammaglobulinemia. Lancet (1985) 1:263-6. doi:10.1016/S0140-6736(85)91037-2
13. Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res (2008) 28:1263-9.
14. van der Meer JW, Weening RS, Schellekens PT, van Munster IP, Nagengast FM. Colorectal cancer in patients with X-linked agammaglobulinemia. Lancet (1993) 341:1439-40. doi:10.1016/0140-6736(93)90883-I
15. Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodeficiencies. J Pediatr (1995) 126:1-10. doi:10.1016/S0022-3476(95)70491-4
16. Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol (1997) 158:977-83.
17. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest (2007) 117:1137-46. doi:10.1172/JCI31405
18. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410:1107-11. doi:10.1038/35074122
19. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science (2001) 294:605-9. doi:10.1126/science.1063916
20. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 6:722-9. doi:10.1038/ni1213
21. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 95:7556-61. doi:10.1073/pnas.95.13.7556
22. Street SE, Trapani JA MacGregor D Smyth MJ Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 196:129-34. doi:10.1084/jem.20020063
23. Smyth MJ Thia KY Street SE MacGregor D Godfrey DI Trapani JA Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 192:755-60. doi:10.1084/jem.192.5.755
24. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet (1978) 2:1323-7. doi:10.1016/S0140-6736(78)91970-0
25. Hoover R Fraumeni JF Jr Risk of cancer in renal-transplant recipients. Lancet (1973) 2:55-7. doi:10.1016/S0140-6736(73)93256-X
26. Birkeland SA Storm HH Lamm LU Barlow L Blohme I Forsberg B et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer (1995) 60:183-9. doi:10.1002/ijc.2910600209
27. Opelz G Dohler B Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 4:222-30. doi:10.1111/j.1600-6143.2004.00451.x
28. List AF Greco FA Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol (1987) 5: 1673-89.
29. Leblond V Davi F Charlotte F Dorent R Bitker MO Sutton L et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol (1998) 16:2052-9.
30. Engels EA Pfeiffer RM Fraumeni JF Jr Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 306:1891-901. doi:10.1001/jama.2011.1592
31. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A O Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation (1996) 61:715-21. doi:10.1097/00007890-199603150-00008
32. Krynitz B, Edgren G, Lindelof B, Baecklund E, Brattstrom C, Wilczek H, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008 - a Swedish population-based study. Int J Cancer (2013) 132:1429-38. doi:10.1002/ijc.27765
33. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol (2002) 147:950-6. doi:10.1046/j.1365-2133.2002.04976.x
34. Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer (2009) 125:1755-63. doi:10.1002/ijc.24741
35. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst (2005) 97:425-32. doi:10.1093/jnci/dji072
36. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 52:611-22. doi:10.1097/QAI.0b013e3181b327ca
37. Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, Brown ST, et al. HIV as an independent risk factor for incident lung cancer. AIDS (2012) 26:1017-25. doi:10.1097/QAD.0b013e328352d1ad
38. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a Prospective Cohort Study. Lancet Oncol (2009) 10:1152-9. doi:10.1016/S1470-2045(09)70282-
39. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 12:298-306. doi:10.1038/nrc3245
40. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313:1960-4. doi:10.1126/science.1129139
41. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 348:203-13. doi:10.1056/NEJMoa020177
42. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res (2008) 14:5220-7. doi:10.1158/1078-0432.CCR-08-0133
43. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer (2008) 113:1387-95. doi:10.1002/cncr.23712
44. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol (2011) 29:1949-55. doi:10.1200/JCO.2010.30.5037
45. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res (1998) 58:3491-4.
46. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res (2003) 63:1555-9.
47. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer (2006) 94:275-80. doi:10.1038/sj.bjc.6602934
48. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 10:99-111. doi:10.1016/j.ccr.2006.06.016
49. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A (2012) 109:2802-7. doi:10.1073/pnas.1108781108
50. Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 73:3499-510. doi:10.1158/0008-5472.CAN-13-0371
51. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res (2007) 13:1472-9. doi:10.1158/1078-0432.CCR-06-2073
52. Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, Jeon YK, et al. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer (2008) 98:1118-24. doi:10.1038/sj.bjc.6604256
53. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res (2000) 60:5857-61.
54. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol (2005) 23:8959-67. doi:10.1200/JCO.2005.01.4910
55. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science (2013) 339:1546-58. doi:10.1126/science.1235122
56. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 321:1801-6. doi:10.1126/science.1164368
57. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 321:1807-12. doi:10.1126/science.1164382
58. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science (2006) 314:268-74. doi:10.1126/science.1133427
59. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science (2007) 318:1108-13. doi:10.1126/science.1145720
60. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 150:1121-34. doi:10.1016/j.cell.2012.08.024
61. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 43:442-6. doi:10.1038/ng.810
62. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (1999) 284:1351-4. doi:10.1126/science.284.5418.1351
63. Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med (1999) 189:1659-68. doi:10.1084/jem.189.10.1659
64. Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A (2001) 98:13255-60. doi:10.1073/pnas.231326898
65. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 269:1281-4. doi:10.1126/science.7652577
66. Echchakir H, Mami-Chouaib F, Vergnon I, Baurain JF, Karanikas V, Chouaib S, et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res (2001) 61:4078-83.
67. Hogan KT, Eisinger DP, Cupp SB III, Lekstrom KJ, Deacon DD, Shabanowitz J, et al. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res (1998) 58:5144-50.
68. Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res (2001) 61: 3718-24.
69. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood (2001) 98:2887-93. doi:10.1182/blood.V98.10.2887
70. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A (1995) 92:11810-3. doi:10.1073/pnas.92.25.11810
71. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer (1998) 76:652-8. doi:10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9
72. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today (1997) 18:89-95. doi:10.1016/S0167-5699(96)10075-X
73. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest (1991) 87:284-92. doi:10.1172/JCI114984
74. Perez B, Benitez R, Fernandez MA, Oliva MR, Soto JL, Serrano S, et al. A new beta 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens (1999) 53:569-72. doi:10.1034/j.1399-0039.1999.530607.x
75. Jimenez P, Canton J, Collado A, Cabrera T, Serrano A, Real LM, et al. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer (1999) 83:91-7. doi:10.1002/(SICI)1097-0215(19990924)83:1<91::AID-IJC17>3.0.CO;2-4
76. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 505:495-501. doi:10.1038/nature12912
77. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol (2013) 14:e218-28. doi:10.1016/S1470-2045(12)70582-X
78. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, et al. TGF-beta: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 106:djt369. doi:10.1093/jnci/djt369
79. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 3:991-8. doi:10.1038/ni1102-991
80. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 285:727-9. doi:10.1126/science.285.5428.727
81. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A (1996) 93:12445-50. doi:10.1073/pnas.93.22.12445
82. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 31:413-41. doi:10.1146/annurev-immunol-032712-095951
83. Shafi S, Vantourout P, Wallace G, Antoun A, Vaughan R, Stanford M, et al. An NKG2D-mediated human lymphoid stress surveillance response with high interindividual variation. Sci Transl Med (2011) 3:113ra124. doi:10.1126/scitranslmed.3002922
84. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 436:1186-90. doi:10.1038/nature03884
85. Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol (2006) 176:5108-16. doi:10.4049/jimmunol.176.8.5108
86. Liu XV, Ho SS, Tan JJ, Kamran N, Gasser S. Ras activation induces expression of Raet1 family NK receptor ligands. J Immunol (2012) 189:1826-34. doi:10.4049/jimmunol.1200965
87. Vantourout P, Willcox C, Turner A, Swanson CM, Haque Y, Sobolev O, et al. Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway. Sci Transl Med (2014) 6:231ra249. doi:10.1126/scitranslmed.3007579
88. Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med (2012) 209:2409-22. doi:10.1084/jem.20120565
89. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A (1999) 96:6879-84. doi:10.1073/pnas.96.12.6879
90. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer (2003) 104:354-61. doi:10.1002/ijc.10966
91. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A (2001) 98:11521-6. doi:10.1073/pnas.201238598
92. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. RAE1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature (2001) 413:165-71. doi:10.1038/35093109
93. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med (2005) 202:583-8. doi:10.1084/jem.20050994
94. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 28:571-80. doi:10.1016/j.immuni.2008.02.016
95. Chen D, Juko-Pecirep I, Hammer J, Ivansson E, Enroth S, Gustavsson I, et al. Genome-wide association study of susceptibility loci for cervical cancer. J Natl Cancer Inst (2013) 105:624-33. doi:10.1093/jnci/djt051
96. Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology (2008) 47:90-6. doi:10.1002/hep.21964
97. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 342:1432-3. doi:10.1126/science.342.6165.1432
98. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466
99. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364:2517-26. doi:10.1056/NEJMoa1104621
100. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443-54. doi:10.1056/NEJMoa1200690
101. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 366:2455-65. doi:10.1056/NEJMoa1200694
102. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369:122-33. doi:10.1056/NEJMoa1302369
103. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (2014) 343:152-7. doi:10.1126/science.1246886